Lykos Therapeutics, a company dedicated to transforming mental healthcare, is reorganizing as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults.   This reorganization is happening in response to the FDA’s recently issued complete response letter (CRL) for the NDA for midomafetamine capsules for the treatment of PTSD in adults. The FDA communicated that it had completed its revi...